Key Financial Data Of Group

Oncolys BioPharma Inc. - Filing #7310662

Concept As at
2024-06-30
2024-01-01 to
2024-06-30
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-06-30
2023-01-01 to
2023-06-30
Key financial data of group
Business results of group
Net sales
31,384,000 JPY
63,038,000 JPY
63,038,000 JPY
Ordinary profit (loss)
-752,997,000 JPY
-1,913,816,000 JPY
-867,441,000 JPY
Net assets
1,417,002,000 JPY
1,474,097,000 JPY
1,290,506,000 JPY
Total assets
1,885,725,000 JPY
2,040,598,000 JPY
1,866,628,000 JPY
Basic earnings (loss) per share
-36.96
-108.92
-50.16
Diluted earnings per share
Equity-to-asset ratio
0.747 xbrli:pure
0.715 xbrli:pure
0.687 xbrli:pure
Net cash provided by (used in) operating activities
-1,124,153,000 JPY
-1,336,922,000 JPY
-451,552,000 JPY
Net cash provided by (used in) investing activities
-1,184,000 JPY
-5,392,000 JPY
-748,000 JPY
Net cash provided by (used in) financing activities
686,458,000 JPY
1,142,542,000 JPY
45,445,000 JPY
Cash and cash equivalents
872,457,000 JPY
1,287,763,000 JPY
1,090,340,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.